Pure oestrogen antagonists for the treatment of advanced breast cancer.

@article{Howell2006PureOA,
  title={Pure oestrogen antagonists for the treatment of advanced breast cancer.},
  author={A Howell},
  journal={Endocrine-related cancer},
  year={2006},
  volume={13 3},
  pages={
          689-706
        }
}
For more than 30 years, tamoxifen has been the drug of choice in treating patients with oestrogen receptor (ER)-positive breast tumours. However, research has endeavoured to develop agents that match and improve the clinical efficacy of tamoxifen, but lack its partial agonist effects. The first 'pure' oestrogen antagonist was developed in 1987; from this, an even more potent derivative was developed for clinical use, known as fulvestrant (ICI 182,780, 'Faslodex'). Mechanistic studies have shown… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 64 CITATIONS, ESTIMATED 58% COVERAGE

Identifying Genes Responsible for Tamoxifen Resistance in Breast Cancer

VIEW 6 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2005
2018

CITATION STATISTICS

  • 6 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 115 REFERENCES

GnantMF, Jakesz R&Zielinski CC 2005 (‘Faslodex’) in pre-treated patients with advanced breast cancer

GG Steger, R Bartsch, +4 authors GJ Locker
  • European Journal of Cancer
  • 2005
VIEW 11 EXCERPTS
HIGHLY INFLUENTIAL